Original ArticlesSexual Dysfunction in Hypertensive Patients Treated with Losartan
Section snippets
Study Design and Patient Population
Three hundred twenty-three patients with uncontrolled hypertension (blood pressure ≥ 140/90 mm Hg) (197 men, 126 women) attending primary care clinics were screened for sexual dysfunction using a self-administered questionnaire (“symptom-finding” questionnaire) validated in a pilot study conducted in another 64 subjects (see below). From the pool of 197 male subjects, 82 male subjects were diagnosed as suffering from sexual dysfunction (prevalence, 42.3%; 95% confidence interval, 35.3–49.3). Of
Sample Characteristics
General characteristics of both intervention and control subjects completing the study are given in Table 1. The control and interventional groups were comparable with regard to age, marital status, educational level, and duration of hypertension treatment. Group systolic and diastolic blood pressures at the initiation of the study averaged 153 ± 13/89 ± 8 mm Hg (mean ± 1SD) and 155 ± 12/89 ± 8 mm Hg in subjects reporting negative and positive histories of sexual dysfunction, respectively (P > 0.05).
Before
Discussion
A man’s sexual response reflects a dynamic balance between excitatory and inhibitory forces. Any physiological or organic disturbance in the network of peripheral and central mechanisms regulating erection and detumescence has a clear effect on sexual function.21 Both high blood pressure and antihypertensive medications are among the various disorders associated with sexual dysfunction.6., 7., 18. In keeping with these observations, the prevalence of sexual dysfunction attributed to the use of
Acknowledgments
We are grateful for the careful assistance provided by Carla Yunis, M.D., M.P.H., for her valuable comments regarding data analysis and interpretation of findings. This study was supported in part by Merck Sharpe and Dohme de Espana SA who provided drugs used and paid for statistical analysis.
References (34)
Assessing patient wellness: new perspectives on quality of life and compliance
Am J Hypertens
(1998)- et al.
Angiotensin II antagonists for hypertension: Are there differences in efficacy?
Am J Hypertens
(2000) - et al.
The prevalence and etiology of impotence in 101 male hypertensive outpatients
Am J Hypertens
(1999) - et al.
Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study (MMAS)
J Urol
(1994) - et al.
Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum
J Urol
(1997) - et al.
Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension
Clin Ther
(1996) - et al.
Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients
Am J Hypertens
(1999) - et al.
The effects of replacing β-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients
Am J Hypertens
(1996) - et al.
Superiority of nonpharmacologic therapy compared to propranolol and placebo in men with mild hypertension: a randomized, prospective trial
Am Heart J
(1992) - et al.
Treatment of mild hypertension study
JAMA
(1995)
Hypertension treatment compliance: what do patients want to know about their medications?
Prog Cardiovasc Nurs
Compliance in the treatment of hypertension: a need for action
Am J Hypertens
Sexual symptoms in hypertensive patients. A clinical trial of antihypertensive medications
Arch Intern Med
The sexual functioning of elderly hypertensive women
J Sex Marital Ther
Erectile dysfunction in hypertensive subjects. Assessment of potential determinants
Hypertension
Sexual sequelae of antihypertensive drugs: treatment effects on self-report and physiological measures in middle-aged male hypertensives
Arch Sex Behav
Effect of frequently prescribed cardiovascular medications on sexual function: a pilot study
Ann Pharmacother
Cited by (134)
Ficus plants in the Co-management of Hypertension and Erectile dysfunction
2021, Phytomedicine PlusCitation Excerpt :Similarly, angiotensin converting enzyme inhibitors responsible for blocking angiotensin II generation and subsequent aldosterone production, with quinapril seen in improving erection in patients with ED and arteriosclerosis (Speel et al., 2005). Major angiotensin receptor blockers namely Losartan and Irbesartan actually improves sexual function in hypertensive patients (Baumhakel et al., 2011); (Llisterri et al., 2001). The positive effect of PDE-5 inhibitors on the penile help serve in the regulation of blood pressure by ensuring the continuous bio-availability of NO. Despite the remarkable therapeutic efforts in managing ED, it is evident that a relative proportion of patients with erectile dysfunction will fail to respond to oral pharmacotherapy including PDE-5 inhibitors (Hernández-Cerda et al., 2020).
Pharmacology and perspectives in erectile dysfunction in man
2020, Pharmacology and TherapeuticsOral administration of Tridax procumbens aqueous leaf extract attenuates reproductive function impairments in L-NAME induced hypertensive male rats
2017, Middle East Fertility Society JournalVasculogenic Erectile Dysfunction
2013, Vascular Medicine: A Companion to Braunwald's Heart Disease: Second Edition